Site Investigator, Evan Dunn, M.D., shares more about the global Phase 3 #LUGANO clinical trial and potential impact of a more durable #WetAMD treatment option for patients.?? ? EyePoint Pharmaceuticals has partnered with Dr. Dunn to share his own views for educational purposes only; his statements are not intended as medical advice.
